Commented Articles

PanNASH covers commented articles ans publications to acquire sufficient information, understanding, and skills to cope with NASH/NAFLD healthcare demands.

Prevalence of steatosis and fibrosis in young adults in the UK

The study by KWM Abeysekera et al. (Population Health Sciences, Bristol Medical School, University of Bristol, and University Hospitals Bristol NHS Foundation Trust, Bristol, UK) is the first to determine the prevalence of NAFLD in young adults with use of transient electrography, in an age group in which NAFLD burden is poorly characterized...
Read MorePrevalence of steatosis and fibrosis in young adults in the UK

NAFLD patients: cost effectiveness of different strategies for detecting cirrhosis

Several strategies are available for detecting cirrhosis in patients with NAFLD, but their cost effectiveness is not clear. E. Vilar-Gomez et al. (Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA) developed a decision model to...
Read MoreNAFLD patients: cost effectiveness of different strategies for detecting cirrhosis

Randomized Control Trial: Fecal microbiota transplantation in NAFLD patients

The gut microbiome plays a role in metabolism and maintaining gut barrier integrity, and fecal microbiota transplantation can be used to alter the gut microbiome. The authors hypothesized that a fecal microbiota transplantation from a thin and healthy donor given to patients with NAFLD...
Read MoreRandomized Control Trial: Fecal microbiota transplantation in NAFLD patients

From NASH to hepatocellular carcinoma

End-stage NAFLD with liver cancer has an abysmal prognosis and effective medical therapies are lacking, therefore a better understanding of the disease mechanisms will ultimately help to improve patients’ care. The pathogenesis of NAFLD and transition to HCC is multifactorial, yet inflammation is considered a key element...
Read MoreFrom NASH to hepatocellular carcinoma

Type 2 Diabetes, NAFLD, and cardiovascular risk

Patients with T2DM and NAFLD exhibit higher risk of CVD compared with T2DM without NAFLD. In their review, C. Caussy et al. (Hopital Lyon Sud, France) underline that several studies have provided evidence that NAFLD could be an independent cardiovascular risk factor. A potential synergistic increase of cardiovascular risk between...
Read MoreType 2 Diabetes, NAFLD, and cardiovascular risk

Hepatic fibrosis, cardiometabolic risk factors: The Framingham Heart Study

Liver stiffness, as assessed by vibration-controlled transient elastography (VCTE), correlates with hepatic fibrosis, an important predictor of liver-related and all-cause mortality. Although liver fat is associated with cardiovascular risk factors, the association between hepatic fibrosis and cardiovascular risk factors is less clear...
Read MoreHepatic fibrosis, cardiometabolic risk factors: The Framingham Heart Study

HSI screening for metabolic steatopathy in patients with T2D

The purpose of this study by H. Fennoun et al. (University Hospital, Casablanca, Morocco) was to determine the interest of hepatic steatosis index in the detection of hepatic steatosis in patients with type 2 diabetes in order to establish an appropriate screening program of this disease in the population of diabetics hospitalized in Morocco...
Read MoreHSI screening for metabolic steatopathy in patients with T2D

Liver regeneration and nanotubes: an intercellular communication

Human mesenchymal stromal cells are adult stem cells, which feature hepatotropism. They support liver regeneration through amelioration of hepatic inflammation and lipid accumulation in a mouse model of NASH. To study mesenchymal stromal cells actions on fatty liver mechanistically, MJ Hsu et al...
Read MoreLiver regeneration and nanotubes: an intercellular communication